GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » Shiller PE Ratio

SELLAS Life Sciences Group (FRA:RXK3) Shiller PE Ratio : (As of May. 05, 2025)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


SELLAS Life Sciences Group Shiller PE Ratio Historical Data

The historical data trend for SELLAS Life Sciences Group's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group Shiller PE Ratio Chart

SELLAS Life Sciences Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SELLAS Life Sciences Group Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SELLAS Life Sciences Group's Shiller PE Ratio

For the Biotechnology subindustry, SELLAS Life Sciences Group's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SELLAS Life Sciences Group's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's Shiller PE Ratio falls into.


;
;

SELLAS Life Sciences Group Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

SELLAS Life Sciences Group's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, SELLAS Life Sciences Group's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.076/133.1571*133.1571
=-0.076

Current CPI (Dec. 2024) = 133.1571.

SELLAS Life Sciences Group Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -2,217.622 99.621 -2,964.152
201506 -2,673.027 100.684 -3,535.148
201509 -2,940.329 100.392 -3,899.988
201512 -3,304.833 99.792 -4,409.774
201603 -2,478.505 100.470 -3,284.853
201606 774.308 101.688 1,013.930
201609 -882.099 101.861 -1,153.118
201612 -696.787 101.863 -910.855
201703 -169.702 102.862 -219.683
201706 -200.250 103.349 -258.006
201709 -188.777 104.136 -241.387
201712 12.953 104.011 16.583
201803 -67.718 105.290 -85.641
201806 -53.928 106.317 -67.542
201809 -22.925 106.507 -28.661
201812 -26.584 105.998 -33.395
201903 -9.841 107.251 -12.218
201906 -5.602 108.070 -6.902
201909 -2.433 108.329 -2.991
201912 -1.314 108.420 -1.614
202003 -0.597 108.902 -0.730
202006 -0.586 108.767 -0.717
202009 -0.450 109.815 -0.546
202012 -0.230 109.897 -0.279
202103 -0.134 111.754 -0.160
202106 -0.249 114.631 -0.289
202109 -0.383 115.734 -0.441
202112 -0.372 117.630 -0.421
202203 -0.953 121.301 -1.046
202206 -0.388 125.017 -0.413
202209 -0.343 125.227 -0.365
202212 -0.406 125.222 -0.432
202303 -0.439 127.348 -0.459
202306 -0.286 128.729 -0.296
202309 -0.309 129.860 -0.317
202312 -0.229 129.419 -0.236
202403 -0.193 131.776 -0.195
202406 -0.121 132.554 -0.122
202409 -0.090 133.029 -0.090
202412 -0.076 133.157 -0.076

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


SELLAS Life Sciences Group  (FRA:RXK3) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


SELLAS Life Sciences Group Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


SELLAS Life Sciences Group Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group Headlines

No Headlines